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To my big messy family, 
to my solid roots 
and to myself 
 
“…unless it comes out of 
your soul like a rocket, 
unless being still would 
drive you to madness or 
suicide or murder, 
don't do it. 
Unless the sun inside you is 
burning your gut, 
don't do it.” 
 
So you want to be a writer 
Charles Bukowski 
 
  
ABSTRACT 
Ovarian cancer is the seventh most common malignancy in women worldwide and the most 
lethal gynaecological malignancy in developed countries. The epithelial subtype is divided in 
five main histologic groups, of which the high-grade serous is the most common subtype. 
Advanced stage at diagnosis, poor prognosis and high incidence of resistance to therapy 
constitute the most important challenges for patients with ovarian cancer. The search to identify 
new prognostic and predictive markers represents one of the major goals in the research field of 
high-grade serous ovarian cancer (HGSOC).    
During tumour development and progression, the ovarian stroma, constituted by blood vessels, 
fibroblasts, smooth muscle cells and connective tissue, sustains cancer cells through synergistic 
paracrine communications. This thesis aimed at studying the components of tumour 
microenvironment in serous ovarian cancer, especially HGSOC, and their possible association 
with survival and response to therapy. 
We identified PDGFR positive stroma fibroblasts and perivascular cells as a determinant of 
poor survival in serous ovarian cancer. When we characterized PDGFR positive stroma and 
vasculature of ovarian cancer, compared to renal and colorectal cancer, we found both 
similarities and differences. We also studied the interaction between cancer-associated 
fibroblasts and immune cells and noted an inhibitory effect of FAP positive fibroblasts in 
patients with high tumour infiltration of CD8 positive T cells on response to platinum-based 
treatment in a population of HGSOC patients. On the same population, we studied the 
macrophage profile and discovered a correlation of two distinct subtypes of macrophages 
(CD11c and CD80 positive) in specific tumour localizations, with overall and progression-free 
survival respectively, indicating independent effects of these subsets on natural course of the 
disease and response to treatment. 
In summary, our research identified a number of tumour stroma-related measurable features 
associated with survival and response to treatment. Our findings support continued analyses of 
ovarian cancer tumour microenvironment in order to discover and develop new prognostic and 
predictive tools, to improve the clinical outcome in ovarian cancer. 
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1. OVARIAN CANCER 
1.1 EPIDEMIOLOGY 
Ovarian cancer is the seventh most common malignancy in women worldwide, with around 
250.000 women diagnosed every year and 150.000 deaths [1]. It is the most lethal among the 
gynaecological malignancies in developed countries. The relative 5-year survival across all 
stages in Europe is 38% [2] and 43% in Sweden  [3]. Northern Europe has the highest 
incidence with 10 cases per 100.000 women and in Sweden around 700 women are 
diagnosed with ovarian cancer per year. The incidence is low below 30 years of age and 
reaches a peak for women between 65 and 74 years old. Ninety percent of all the ovarian 
tumours are of epithelial origin, epithelial ovarian carcinomas (EOC).  Due to the lack of 
symptoms when the cancer is localized, most women are diagnosed when the tumour has 
spread outside the pelvis (FIGO stage III-IV).  
1.2 HISTOPATHOLOGY 
EOC encompasses five distinct subtypes:  high-grade serous, low-grade serous, endometrioid, 
clear cell and mucinous subtype [4].  High-grade serous ovarian carcinomas (HGSOC) 
account for approximately 70% of ovarian epithelial carcinomas [4]. Until a few years ago, 
the old three tiers grading system divided serous ovarian cancers into high, moderate and low 
differentiated tumours, but since 2012 a new two grading system is used, classifying serous 
ovarian cancer into low- and high- grade subtype [5] [6].  The two low-grade and high-grade 
types represent distinct different subtypes with specific molecular and clinical characteristics 
[7] [8]. Furthermore, the origin and the genetic mutation patterns allow EOC to be divided in  
type I and type II tumours [9]. Type I tumours are represented by low-grade serous, low-
grade endometrioid, clear cell and mucinous carcinomas, that are thought to develop in a 
stepwise fashion from precursor lesions. Type II tumours, instead, are represented by 
HGSOC, high-grade endometrioid carcinoma, malignant mixed mesodermal tumours 
(carcinosarcomas) and undifferentiated carcinomas, which grow rapidly and are highly 
aggressive [10]. 
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1.3 HIGH-GRADE SEROUS OVARIAN CANCER 
HGSOC are the prototype of type II lesions and are thought to originate from ovarian 
epithelium, distal fallopian tube or peritoneum [10]. P53 dysfunctions caused by mutations or 
post-translational modifications are almost ubiquitous in this type of tumours. Mutations in 
the TP53 gene have been shown in 95% of these tumours and in the remaining cases p53 
dysfunction is caused by posttranslational mechanisms [10] . The existence of a pre-tumoral 
lesion found in the tuba, called serous tubal intraepithelial carcinoma (STIC), characterized 
by the so called ”p53 signature”, is the reason for considering distal tuba as the site of origin 
of most of the HGSOC.  
A second genetic marker for HGSOC is BRCA pathway dysfunction which affects half of the 
cases [11] and can be represented by germline mutations, somatic mutations, or epigenetic 
silencing.  Germline mutation of BRCA, according to the Cancer Genome Atlas Research 
Network study, were seen in 17% of the HGSOC, while somatic mutations of BRCA in the 
3%; in other 11% BRCA1 was epigenetically silenced [11] [10]. In general, defective 
homologous recombination DNA repair systems can account for different alterations that go 
under the name of ”BRCAness” . Other altered pathways involve RAD51C, EMSY, PTEN 
Retinoblastoma [12], PI3K/Akt and Notch signalling cascades can be often altered as 
amplifications of the cell cycle regulator cyclin E1 gene (CCNE1) [13].   
1.4 RISK FACTORS 
The most important known risk factors for EOC are age, hereditary mutations, null-parity, 
certain gynaecological conditions like endometriosis, and hormonal replacement treatment.  
A family history of ovarian cancer of having one affected first-degree relative diagnosed with 
ovarian cancer is associated with a 2 to 3 fold increased risk of being diagnosed with ovarian 
cancer [14]. At certain high risk of developing EOC are women with breast cancer 
susceptibility protein (BRCA) 1 and 2 germline mutations. For carriers of BRCA1 mutation 
the risk of developing EOC before the age of 70 is around 30-40% [15] [16]. The 
corresponding risk for BRCA 2 mutation is 10-20%. Women with BRCA 1 and 2 mutations 
[17] are recommended to consider prophylactic surgical removal of ovaries and tubes after 
childbearing age. Although the inherited syndromes that involve mutations in mismatch 
repair genes, like hereditary non-polyposis colorectal cancer (HPNCC) (also named the 
Lynch syndrome), [18] mostly affect the risk of colon cancer and endometrial cancer, women 
with Lynch syndrome also have a 12% risk of developing EOC [19] [20].  
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Women with endometriosis have an increased risk of EOC, especially of the clear cell and 
endometrioid sub type of EOC [18] [21].   
Hormone replacement therapy based on oestrogen with or without progestin, slightly 
increases the risk of ovarian cancer. A Danish prospective cohort study of hormone 
replacement therapy users reported an EOC incidence rate ratio (RR) of 1.44 (95% CI 1.30-
1.58) compared to never users [22]. The protective effect of oral contraception increases with 
duration of use (6% reduction risk per year) [23] and the risk reduction seems to persist for 
more than 30 years after ceased use [24]. Oral contraception may in fact be used as 
chemoprevention for BRCA1/2 mutation carriers [25]. 
 In a meta-analysis conducted on 47 studies, it emerged that the relative risk of ovarian cancer 
was increased with the increase of both height and body mass index [26]. Parity [20] and 
breastfeeding [20], [27] can be considered as protective factors.  A full-term pregnancy can 
reduce the risk of developing ovarian cancer up to one third, and additional pregnancies 
reduce the risk further [20] . 
1.5 STANDARD PRIMARY TREATMENT 
Primary surgery is the cornerstone of treatment for EOC. Surgery includes removal of uterus, 
tubes, ovaries, omentum, biopsies of peritoneum and all visible tumour lesions. Pelvic and 
para-aortal lymph node removal is performed when pre-operative suspected stage I (except 
for mucinous subtype). Advanced stage disease often requires a more extensive surgery with 
multiple bowel incisions, splenectomy and stripping of the peritoneal surface in order to 
obtain macroscopic radical surgery.  If the extents of the disease don´t allow a proper 
debulking, the surgery can be preceded by two to four cycles of neoadjuvant chemotherapy 
(the surgery is then named delayed primary or interval surgery) [28].  
Only patients with confined disease stage IA-B and certain histology subtypes, are subjected 
to surgery without any adjuvant chemotherapy. The great majority of patients receive 
chemotherapy after surgery [29].  The standard treatment is a combination of platinum and 
taxanes [30].  Current standard post-operative chemotherapy consists of six cycles of 
carboplatin-paclitaxel [31] [32]) administered intravenously every three weeks. According to 
recent evidences [33], [34] bevacizumab, a monoclonal antibody against VEGF, is approved 
in combination with paclitaxel and carboplatin, followed by mono-treatment in maintenance 
regime for 12-15 months, in primary treatment of epithelial ovarian cancer stage IIIC with 
presence of residual tumour after debulking surgery, or in stage IV. 
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Resistance to therapy is a major problem, since approximately 75% of advanced epithelial 
ovarian cancers will relapse within three years [35]. According to treatment sensitivity, 
tumours can be classified in refractory, resistant and sensitive to platinum, on the basis of the 
time interval between the last course of platinum and relapse or progression, called the 
platinum-free Interval (PFI). Relapse/progression after 6 months of PFI categorizes a patient 
as platinum sensitive, and these patients will likely respond to a second line of platinum 
treatment. A tumour progressing on platinum based therapy in less than 6 months from the 
last course is classified as resistant, associated with worse prognosis. A tumour not even 
initially responding but relapsing or progressing during the platinum treatment is considered 
refractory.  
 
 
Figure 1: Ovarian cancer FIGO stage IIIC. The cancer is found in one or both ovaries and has in this case spread 
to the omentum (> 2 centimeters) and the peritoneum. The cancer may have spread to lymph nodes behind the 
peritoneum, or to the surface of liver or spleen. Figure adapted from National Cancer Institute (NCI) website 
https://goo.gl/images/SQBJNi 
 
1.6 PROGNOSTIC FACTORS AND MARKERS 
Few prognostic biomarkers, and clinical markers, have been established for EOC mostly due 
to the heterogeneity of the disease. The most important predictor of survival is stage at 
diagnosis. Overall survival at five years for EOC range from 90% in stage IA to 20% in stage 
IV [36]. Age, histology, grade and residual disease after surgery are all established significant 
prognostic clinical factors for ovarian cancer [37]. Regarding prognostic biomarkers, a few of 
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them have so far been established. Currently there is no biomarker fully accepted and 
recognized to guide the choice of therapy in ovarian cancer. Cancer Antigen 125 (CA 125) is 
a valuable serum biomarker for tumour detection and monitoring [38]. Positive oestrogen 
receptor or progesterone receptor expressions have been associated with improved survival in 
endometrioid carcinoma [39].  Serum VEGF and PDGF have been recently studied as 
prognostic biomarkers, with some encouraging results. Elevated serum VEGF levels have 
been associated with poor progression-free survival (PFS) (HR 2.46, Cl 95% 1.84-3.29), 
showing a higher impact in the early stages [40, 41]. The different prognosis shown by 
HGSOC has aroused questions about the existence of different molecular subtypes in this 
class of ovarian cancers. Verhaak and colleagues [42] used a dataset from 489 HGSOC 
included in the Cancer Genome Atlas Research Network study [11] to develop gene 
signatures related to different subtypes with different prognosis. The gene signatures were 
divided into subtypes called: differentiated, immunoreactive, mesenchymal and proliferative, 
with the immunoreactive group having the best prognosis and the mesenchymal one having 
the worse prognosis.  
1.7   PREDICTIVE MARKERS 
HGSOC patients with BRCA mutations, especially BRCA 2, have been shown to have a 
higher response rate to chemotherapy and a better survival in general [43].  Furthermore, 
BRCA mutations are the main predictive marker for PARP inhibitors therapy, due to the 
”synthetic lethality”.  
In conclusion, there is an impelling need for the search of new prognostic and predictive tools 
to be included in the management of ovarian cancer. The supportive stromal network, 
underling and surrounding tumour cancer cells, has been speculated to be a source of 
available biomarkers both for survival and response to therapy prediction. 
2. TUMOUR MICROENVIRONMENT 
2.1   INTRODUCTION  
The malignant cancer cell has been the principal topic over the last forty years of cancer 
research, and researcher used to believe in its total centrality in the biology of cancer. In the 
last few years a new vision of the process of tumour initiation and progression has taken 
place, involving the role of what is now called the “tumour microenvironment” or the 
“tumour stroma”. Composed of different kinds of cells, the tumour stroma creates a 
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permissive environment for cancer, vital for its growth and spread and helps in several 
established cancer hallmarks [44]. Currently the tumour microenvironment represents a broad 
and fast moving field, with influences on prognosis and sensitivity to therapy [45, 46]. The 
most important components of the tumour stroma are cancer-associated fibroblasts, 
endothelial cells, perivascular cells, referred to as pericytes, and immune cells. The next 
paragraphs we will focus mostly on these four cell types. 
 
  
Figure 2: A schematic cartoon portraying the various constituent cell types within tumor microenvironment. 
Figure adapted from review of  Pietras and Östman [44]. 
 
2.2 CANCER-ASSOCIATED FIBROBLASTS 
2.2.1 GENERAL BIOLOGY 
Cancer-associated fibroblasts (CAFs) are large spindle-shaped cells, considered, broadly as 
activated fibroblasts within the tumour stroma expressing different myofibroblastic markers 
[47]. The origin of CAFs is under debate, but a few alternative sources seem to be the most 
validated ones: resident fibroblast; epithelial or endothelial cells in trans-differentiation; 
mesenchymal cells such as vascular smooth-muscle cells, pericytes or adipocytes; and finally 
bone marrow derived precursors [47].Their different origins can be translated into different 
subtypes possibly contributing in different ways to the promotion of tumour growth and 
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invasiveness. 
2.2.2 TUMOUR INITIATION 
CAFs can express and secrete signalling molecules, for example mithogenic epithelial growth 
factors as hepatocyte growth factor (HGF), epidermal growth factor (EGF), insulin like 
growth factor 1 (IGF-1), stromal cell derived factor 1 (SDF-1/CXCL12), fibroblast growth 
factors (FGFs) that stimulate cancer cells proliferation [48] [49], contributing to the process 
of cancer initiation. They can also secrete proinflammatory mediators that recruit immunitary 
cells, which in turn provide mitogenic signals to cancer cells [50] [51]. Erez et al. described 
in 2010 a proinflammatory gene signature in CAFs isolated from dysplastic skin. The 
signature was seen also in breast and pancreatic cancers and marked a pathway that promoted 
macrophage recruitment and tumor growth, dependent mostly on the Nf-kb signalling. These 
proinflammatory genes could be expressed by dermal fibroblasts under stimulation by 
carcinoma cells [52]. 
2.2.3  STEM CELLS SUPPORT AND EPITHELIAL TO MESENCHYMAL 
TRANSITION (EMT) 
Vermeulen et al. observed in colon cancer that the Wingless/Integrated (WNT) pathway in 
cancer cells, needed to maintain cell stemness, was particularly active in tumour cells located 
close to stroma fibroblasts [53]. They demonstrated that HGF secreted by tumour stroma 
myofibroblasts activates beta-catenin dependent transcription and cancer stem cells 
clonogenicity. The stem cell phenotype could, in this way, also be rescued in more 
differentiated tumour cells [53]. CAFs are also involved in the process of epithelial to 
mesencymal transition (EMT) via secretion of TGF [54]; they are able to limit cancer cell 
apoptosis [49] [44], in one way secreting IGF-1 and 2 as survival factors, and in a second way 
secreting extracellular matrix (ECM) remodelling proteases that provides non diffusible 
survival signals. 
2.2.4   IMMUNE MODULATION 
The evasion of immune control is another important hallmark capability of tumor cells. 
Preclinical studies suggest that fibroblast activating protein (FAP) positive stromal cells are 
able to induce escape from immunological control by CD8+ T cells. In a model of Lewis lung 
carcinoma it was demonstrated that ablation of FAP positive fibroblasts was able to induce 
hypoxic death mediated by TNF and IFN (normally involved in CD8 positive T cell-
dependent killing) [55]. Another mechanism of escaping immunological control involves the 
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inhibition of cytotoxic T cells and NK/T cells, through TGF  production, as shown by 
Stover et al. in 2007 [56]. Zahng et al in 2016 demonstrated that depletion of FAP+ 
fibroblasts could reduce the metabolic stress of tumour infiltrating lymphocytes (TILs) [57]. 
2.2.5 METABOLIC INTERACTION WITH CANCER CELLS 
CAFs can modulate the energetic metabolism of cancer cells. After stimulation by reactive 
oxygen species secreted by cancer cells, CAFs can switch on aerobic glycolysis and produce 
lactate and pyruvate which in turn can be used as fuel by tumour cells [58]. A model 
proposed by Martinez-Outschoorn et al. considers the existence of a “two compartments 
tumour metabolism” where tumour stroma cells are catabolic and tumour cells are anabolic, 
and the energy is transferred from the catabolic compartment to the anabolic one through 
sharing of nutrients [59]. 
2.2.6   METASTASIS  
Activated fibroblasts can control invasiveness and metastasis through different mechanisms. 
First of all, they can trigger angiogenesis promoting tumour vasculature formation resulting 
in improved tumor growth and spreading. CAFs can produce proangiogenic factors like 
VEGF, FGFs, IL-8/CXCL8 and PDGF-C. For the same purpose they produce ECM 
degrading molecules that release angiogenic factors [60], or chemo attractants for other 
proangiogenic myeloid cells [61]. Fibroblasts have moreover been identified as providers of 
pro-metastatic signalling in a paracrine and in a systemic fashion. Karnoub has showed in 
2007 that secretion of CXCL5 from mesenchymal stem cells previously stimulated by breast 
cancer cells, can enhance in a paracrine way their invasiveness and metastatic potential [62]. 
The metastatic colonization in distant sites is another capability that cancer cells should 
acquire in order to be able to form metastasis. The process of spreading and colonize distant 
organs is not always successful since only a minority of tumour cells that reach distant sites 
can actually settle and form metastatic colonies. Malanchi et al. in 2011 have described the 
crucial role of stromal niche signals in the secondary target organs in the process of 
metastasizing [63]. They identified periostin, produced by fibroblasts, as required for cancer 
stem cell maintenance in distant organs and showed that its blocking could inhibit metastasis 
formation. Several factors are produced and secreted systemically by activated fibroblasts in 
order to enhance the metastatic potential of cancer cells; two of these are represented by 
HGF, the c-Met ligand, that stimulates invasiveness and proliferation and TGF  that enables 
cancer cells to invade [54]. Another example of systemic effects promoted by CAFs in the 
primary tumour site, is the expression of GDF15, a TGF/BMP family member, by prostate 
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cancer-associated fibroblast, which not only exerts paracrine stimulation of tumour cells 
growth and migration, but also instigates their growth in distant sites [64]. 
2.2.7   PROGNOSTIC IMPACT 
Several studies have shown a connection between markers expression of stroma fibroblasts 
and prognosis in different cancer types, like prostate and breast tumours [65].   
Prognostic studies used different techniques to detect biomarkers, focusing either on protein 
expression or on mRNA expression.  
Two studies recognized tumour growth factor  (TGF), detected at a protein level, to be 
related to tumour progression in non-small cell lung cancer [66] [67]. Again in lung cancer, 
platelet derived growth factor A (PDGFA) expression, detected with immunohistochemistry 
on tumour samples, correlated with lymph node metastasis, while co expression of VEGFR-3 
and PDGFB was an independent indicator of poor prognosis [68] [69].  
One of the first studies to use gene expression analysis in order to explore potential stroma 
related signatures was performed by Chang et al in 2004. They detected a gene expression 
profile of fibroblasts from several anatomic sites, which was stereotyped and occurred after 
serum exposure [70]. A microarray analysis performed on normal fibroblasts and cancer 
associated fibroblasts derived from non-small cell lung cancer, revealed around 11 
differentially expressed genes that formed a prognostic gene expression signature, validated 
then in clinical datasets [71] Frings et al. described a gene expression signature expressed by 
PDGF activated fibroblasts able to identify a breast cancer subset with a specific prognosis 
pattern [72]. The PDGF signature score proved to be associated with clinical characteristics 
such as human epidermal growth factor 2 positivity, oestrogen receptor negativity, high 
tumour grade and large tumour size. The signature proved to be related with shorter survival 
[72]. 
Recently a growing body of evidence leans in favour of the existence of multiple cancer-
associated fibroblasts subtypes behaving in different way sin relation to cancer cells. Ozdemir 
et al in 2014 showed in a mouse model of pancreas cancer that targeting -SMA positive 
myofibroblasts lead to a more invasive tumour phenotype [73]. CAFs depletion, in this study, 
generated increased hypoxia, enhanced epithelial to mesenchymal transition and determined 
reduced survival of the animals.  
   18 
2.2.8   RESPONSE TO THERAPY 
CAFs have recently been shown to be involved in modulating sensitivity of cancer cells to 
therapy. Sun and colleagues have shown that the expression of a component of the Wnt 
family secreted by fibroblasts in the tumour microenvironment of prostate cancer was 
responsible for attenuation of chemotherapy response in vivo [74]. More recently it was 
proven the ability of CAFs to modulate sensitivity of tumour cells to new target therapies. 
Straussman and colleagues in 2012 characterized a stroma-derived pattern of resistance of 
BRAF mutated melanoma cells to RAF inhibitors [75]. Subsequent proteomic analyses 
identified the responsible secreted factor as HGF, acting on MET receptor and activating the 
AKT pathway. New evidences show influence of CAFs on response to endocrine treatment 
for breast cancer [76]. A new intriguing theory suggests that stromal cells can influence 
breast cancer cells sensitivity to treatment through paracrine and juxtacrine signalling upon 
exosome transfer [77]. Another study found an association between loss of stromal caveolin 1 
and poor clinical outcome in breast cancer suggestive of tamoxifen resistance. This feature in 
the subgroup of lymph node positive patients was related to an 11.5 fold reduction of 5- years 
progression free survival [78]. A recent work from Paulsson et al showed that high expression 
of stromal PDGFRß confers reduced sensitivity to adjuvant tamoxifen, in two large cohorts of 
women affected by breast cancer [79]. These evidences constitute the basis to investigate new 
therapeutic approaches to target cancer-associated fibroblasts. 
2.3 ENDOTHELIAL CELLS 
2.3.1 GENERAL BIOLOGY OF ANGIOGENESIS 
The so called ”angiogenic switch” is a well-known trigger for tumour growth, because it 
increases cancer cells proliferation and sustains the real formation of the tumour mass [80]. 
Also well known is that inhibiting this switch can result in arresting tumour growth possibly 
because of the reduced flow of mitogenic growth factors usually provided through the blood 
flow [81] [82]. Another important role of tumour vessels is to provide oxygen, besides 
survival factors, needed by the tumour cells to escape cell death. In fact, induction of 
apoptosis and necrosis are inevitably a result of destruction of tumour vasculature. Vascular 
disrupting agents cause acute hypoxia and massive cell death [83]. Angiogenesis is 
physiologically activated in the embryonic phase and in the female reproductive cycle, 
otherwise it is triggered just in some pathological conditions such wound healing in which 
tissue remodelling is needed [82], and in cancer. During tumour formation, angiogenesis 
occurs with the same mechanisms used in physiological conditions, but it is constitutively 
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activated and lacks of the “normal” regulation, resulting in the formation of irregular, chaotic 
and unstable vessels [84] [85]. Stromal cells have an active part in orchestrating of the 
tumoral angiogenic process. Immune cells are recruited by endothelial cells and interact with 
them producing several soluble factors implicated in regulation of angiogenesis like cytokines 
(VEGF, bFGF, TNF alpha, PDGF and PIGF), chemokines (CXCL 12, IL 8/CXCL8), matrix 
metalloproteinases (MMP 2-7-9-12-14), serine proteases, cysteine cathepsin proteases, DNA-
damaging molecules (reactive oxygen species ROS), histamine and nitric oxide. These 
molecules are fundamental in regulating vessel cells proliferation, survival, motility and 
vessels formation [86]. A class of macrophage renamed as ”tumor associated macrophages 
(TAMs)” is known to regulate angiogenesis through VEGFA production [87]. Stockmann et 
al in 2008 showed how genetic deletion of VEGFA in macrophages determines attenuation 
and ”normalization” of tumour angiogenesis [88]. Another factor produced by TAMs that 
activates and stimulates angiogenesis in some tumours is the VEGF family member PIGF 
[89].  
2.3.2   METASTASIS  
Angiogenesis has a prime role in cancer cells dissemination and metastatization. VEGF was 
first identified as vascular permeability factor that through VEGFR2, loosens tight junctions 
making vessels permeable to leakage of blood in the interstitial sites and to cancer cells to 
enter the circulation. Another mechanism that enables endothelial cells to increase vascular 
permeability is through activation of CCR2+ which responds to CCL2 secreted by tumour 
cells; CCR2 deficiency, in fact, prevents colon carcinoma cells extravasation and metastatic 
dissemination [90]. Hypoxia around vessels also contributes to metastatic dissemination 
through the activation of genes regulated by the hypoxia inducible factor HIF, and the 
inducible nitric oxide synthase iNOS [91]. About distant metastatization it is now believed 
that primary tumours with metastatic potential can precondition vasculature in metastatic sites 
via production of factors such as VEGF, provided systemically. Newer evidences show that 
stimulation of Notch signalling in endothelial cells by tumour cells, can modify endothelial 
cells morphology and function in a way that stimulates cancer cell migration, invasion and 
settling in distant sites [92]. 
2.3.3 THERAPEUTIC IMPLICATIONS 
With these premises the concept of antiangiogenic cancer therapy seems simple and 
straightforward, but its goal should not only be the one of destroying tumor vasculature 
depriving tumor of its nourishment. In fact better clinical outcomes were seen when 
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antiangiogenic drugs have been administered together with chemotherapy or additional drugs 
[93]. An example of that is VEGF-A/ VEGF 2 blockage that determines transient vessel 
remodelling and normalization with increased pericyte coverage, resulting in reduced 
permeability and facilitated drug access [94] [95]. Tavora et al. propose a mechanistic model 
followed by a clinical translation of the same model in which deletion of focal adhesion 
kinase (FAK) in endothelial cells is sufficient to induce tumour cell sensitization to DNA 
damaging therapies in mice. The clinical observation of low blood vessels expression of FAK 
being associated with complete remission in patients affected by lymphoma supports this 
hypothesis [96]. A more extended paragraph about endothelial cells as target of new 
therapeutically approaches will follow in chapter 3.1.4. 
2.4 PERICYTES 
2.4.1   GENERAL BIOLOGY 
Pericytes are defined as the class of cells that surround endothelial cells, constituting part of 
the mural vessel layers. They are usually covered in the same basement membrane as the 
endothelial cells [97], and they can derive from mesoderm, neural crest, bone marrow or 
endothelial cells themselves. They are described as fibroblasts-like with long protrusions 
through which they take contact with endothelial cells, and can be classified in precapillary 
pericytes, mid capillary pericytes and post capillary pericytes. These cells have recently 
shown to express a wide range of markers that might change according to the different times 
of their development and the different tissues they belong to. Among those, the most known 
ones include PDGF receptor beta (PDGFR), alpha smooth muscle actin (-SMA), desmin, 
NG2, and regulator of G protein signalling 5 (RGS 5) [98] [99]. Tumor pericytes are 
characterized by a more loose attachment to endothelial cells and by a specific pattern of 
activated signalling pathways [100]; more of them are involved in their recruitment and 
differentiation like PDGF, transforming growth factor beta (TGF beta), angiopoietin and 
Notch family members. Recruitment of pericytes into tumours and blood vessels is dependent 
on PDGF signalling. Indeed pericytes express PDGFR, which is activated by PDGF usually 
produced by endothelial cells [101].  
2.4.2   METASTATIC PROCESS 
Since one of the most important external regulators of initial phases of tumour growth is 
neovascularization through tube forming, the supporting pericytes play a fundamental role in 
tumour initiation [102]. Their role in tumour growth and spreading though is still yet to be 
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fully elucidated. In B12 melanoma model, the induced up-regulation of PDGF expression in 
cancer cells resulted in an increased pericytes proliferation with enhanced tumor growth 
(despite a normal vessel density) [103]. When PDGF BB ligand overexpression was induced 
in colorectal and pancreatic models, the increase of pericytes coverage was linked to an 
inhibition of tumour growth [104]. The same contrasting effects have been noticed when 
studying the role of pericytes in the metastatic process. Some evidences show that genetically 
pericytes-poor RIP1-Tag2 mice have an increased rate of metastasis from pancreas lesions 
[105]. In a model of breast cancer, it was shown by Keskin et al that depletion of PDGFR 
positive pericytes in early stages of tumour development resulted in decrease of tumour 
growth, while depletion of the same cells in advanced setting, significantly increases lung 
metastasis [106]. Contrasting evidences are offered by Yang and colleagues, when showing 
that a paracrine interaction between perivascular cells and TAMs promotes tumour metastasis 
through the IL-33-ST2-dependent pathway, in tumour xenografts [107] 
2.4.3   PROGNOSTIC IMPACT 
In a broader perspective, pericytes have a role in increasing tumour aggressiveness allowing 
an immune-permissive tumour environment. Hong J et al proved in 2015 that a paracrine 
communication between pericytes and inflammatory cells promotes recruitment of immune 
suppressor MDSC cells in tumour site leading to increase in tumour growth and circulation of 
malignant cells [108]. 
Sinha and colleagues in 2016 provided in vitro and in vivo evidences, supported by large 
human database analysis, that pericytes were able to accelerate tumour growth in xenografts 
models. Moreover, a pericytes mRNA signature was able to predict poor prognosis in two 
serous ovarian cancer patient datasets [109]. 
In two cohorts of patients with clear cell renal cancer, high -SMA positive pericytes 
coverage, was found to be associated with a poor outcome by Cao et al [110]. 
Lately our group has produced some evidences in favour of the prognostic role of 
perivascular cells in survival, in colorectal, renal and ovarian cancer [111] [112, 113]. 
2.4.4  RESPONSE TO THERAPY 
Pericytes have the ability to modulate the efficacy of tumour treatments. It has been shown 
that they can induce survival signals in endothelial cells providing the rational for dual 
targeting of both kinds of cells [114, 115]. Moreover, pericytes can impair immune-
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modulating therapies through regulation of immune cell trafficking [116]. Finally, pericytes 
have been shown by Armulik et al. to regulate some important functions of the blood brain 
barrier; pericytes deficiency in this study caused increased permeability of the barrier to low 
and high molecular mass tracers [117]. 
A higher coverage of -SMA positive pericytes was also related to a better response to 
neoadjuvant bevacizumab in a cohort of breast cancer patients undergoing a phase II trial 
with preoperative anti-angiogenic therapy [118]. 
2.5 IMMUNE CELLS 
2.5.1 GENERAL BIOLOGY IN TUMOUR MICROENVIRONMENT 
Cancer immune surveillance has been a debated argument in tumour biology since the 
beginning of the century. The difficulty in finding proper animal models in order to test the 
hypothesis that the immune system is involved in cancer development has represented an 
obstacle just recently removed. The use of transgenic mouse technology allowed to define a 
dual role of the immune system in tumour development: protection from cancer development 
and promotion of it [119] [120].  
The continuous in vivo investigation culminated in the evidence of the impact of immune 
cells on prognosis of human tumours [121]. A fundamental step in the investigation of the 
immune microenvironment was the analyses of the in situ immune components that 
constitute the tumour immune infiltrate. 
During early tumour development, immune cells start to invade the area; all immune cell 
types participate to this activity: macrophages, dendritic cells, mast cells, natural killers (NK) 
cells, B lymphocytes and effector T cells, including regulatory T cells (T reg) and cytotoxic T 
cells [122]. Different types of immune cells can be found in different areas of the tumour and 
in different stages of tumour development [123]; this suggests the existence of distinct roles 
for immune cells in tumour control, and clinical outcome.   
 CD8 positive cytotoxic T lymphocytes have been generally associated with a good outcome 
in several tumour types, as in ovarian [124] [125], colon [126] [127], and breast cancer 
[128] [129]. 
T reg cells, in general detected by the expression of CD4 and characterized by an immune 
suppressor phenotype, have mostly been related with poor prognosis, in ovarian cancer 
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[130] and breast cancer [131]. The difficulties in detecting this subtype of T cells has 
brought to discrepancies in results of studies on their prognostic significance [132]. 
NK cells have generally a good impact on prognosis, as shown for colorectal, gastric, lung 
and renal cancer [133]  [134, 135], when detected by CD57.  
Infiltrating B cells can have an antitumor effect in breast and ovarian cancers [136] [137], 
but their effect has not yet been determined for most of the other cancer types.  
Tumour microenvironment interacts with T lymphocytes in different ways but this 
communication mostly brings to immune-suppression. This has been clear after the 
discovery that systemic immune response can fail to produce a valuable suppressive 
response in human cancers [138]. In this study, Schreiber et al show that the presence of 
specific CD8+ T lymphocytes recognizing the antigen expressed by melanoma cells, does 
not prevent progression of melanoma itself.  Different events have been suggested to 
generate this immune suppressive effect, one of this being physical exclusion of T CD8+ 
cells from vicinity of cancer cells as suggested in colon [121], ovarian [125] and pancreas 
cancer [139]. The latter study showed that the major players of this interaction are cancer-
associated fibroblasts, although tumour vessels and endothelial cells can contribute to 
regulate extravasation, and accumulation of T effector cells in the tumoral sites [140]. The 
study also revealed that FASL (FAS ligand) is induced by VEGF in tumour vasculature, 
causing an apoptosis-mediated cell death of T cytotoxic cells (T reg might be protected by 
their high expression of apoptosis inhibiting proteins). 
In ovarian cancer, high expression of VEGF and CD267 (an immunoregulatory molecule) 
from the tumour vasculature is related to low infiltration of T cells and worse clinical 
outcome [124] [141].  
Another mechanism through which tumour microenvironment cells suppress T cell 
immunity is via the PD-1- PD-L1 axis. PD-1 antigen is expressed by T lymphocytes and 
limits their activity in peripheral tissues [142] [143]. When PD-1, which is expressed by T 
cells due to their activation, is recognized by some of his ligands, the kinases related to T 
cell activation are inhibited. The two most known ligands for PD are PD-L1 and L2 which 
have been found expressed mostly on cancer cells and myeloid cells [144] [145]. Therapies 
targeting this pathway have been positively associated with good results in several tumour 
types [146]. 
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In such a heterogeneous environment, the balance between immune promoting and immune 
suppressing factors can influence immune cells phenotype and determine the outcome of 
the immune response. A valid example of that is the plasticity of macrophages. 
Macrophages are supposed to originate from circulating precursors [147],  myeloid cells 
and myeloid derived-suppressor cells [148]. Macrophages have different functions in the 
immune infiltrate that go from increasing the antigen availability to its clearance, and are 
modulated by a complex system of cytokines [149]. . They can polarize into different 
subsets expressing different patterns of cytokines, enzymes and markers. Many refer to 
polarized macrophages as ”M1” and ”M2” following the general distinction of T cells in 
Th1 and Th2. According to this very general distinction, the M1 phenotype is driven by 
Th1 cytokines like interferon- and produces pro-inflammatory factors like IL-6, IL-12, IL-
23, and TNF-; moreover, they express high levels of histocompatibility molecules class II 
and I. M2 macrophages are instead supposed to be anti-inflammatory and pro-tumorigenic. 
IL-4, IL-13, IL-10 guide this phenotype usually during late stage tumour progression [150].  
Subtypes of macrophages defined as Tie2 (angiopoietin) - expressing monocytes are 
supposed to have specific angiopoietic functions [151]. 
2.5.2   PROGNOSTIC AND PREDICTIVE IMPACT 
The definition of the role of tumour-associated macrophages in human cancer prognosis has 
been complicated by the detection system used. As T cells, macrophages share several 
membrane markers, expressed at different intensities during different stages of maturation 
[152]. CD68 has broadly been used as a pan- macrophage marker. In more recent studies 
different markers have emerged as macrophage-associated, or as polarized macrophage-
markers. Two examples are CD163 and CD204, related to the M2-subtype, have been 
associated with bad prognosis in pancreatic cancer [153]. Another molecule expressed by 
polarized M2 macrophages is stabilin1, correlated with short survival in colorectal cancer 
[154].  
Association of macrophages with bad prognosis has been widely proven in different tumour 
types [155] [156],  nonetheless in some tumour types like ovarian and gastric, it has been 
shown the opposite [157, 158]. Similar findings have been published for colorectal cancer 
[159]. This difference in prognostic significance might mirror a different contribution from 
different macrophage subpopulations, and suggests the necessity of defining more stringent 
markers to capture the heterogeneity of macrophage subsets. 
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Some evidences of interaction between macrophages and chemotherapy treatment derive 
from lymphoma, and pancreatic cancer. In follicular lymphoma patients with high CD68 
positive cells infiltrate in the tumour site benefit of a better survival if treated with 
doxorubicin-based regimens [160] compared to regimens without doxorubicin [161]. In 
pancreatic cancer, TAM infiltrate determines higher responsiveness to adjuvant 
gemcitabine [162]. However, macrophages do not seem to support in general a better 
response to chemotherapy. Evidences show that M2 macrophages interact with cytotoxic 
agents increasing tumour-promoting mechanisms [163] [164]. In some cases, M2 
macrophages can promote re-growth of tumours after chemotherapy treatment, by 
triggering re-vascularization [165].  
A specific role of subsets of macrophages in response to anti VEGF treatments needs to be 
mentioned.  Macrophages are indeed major producers of VEGF [166]. Hypoxia resulting 
from vessels destruction can trigger recruitment of macrophages, that implement 
angiogenesis through alternative mechanisms [167]. 
2.6 HETEROGENEITY OF TUMOUR STROMA-DERIVED CELLS 
Based on the multitude of activities performed by tumour stroma cells, it is easy to deduce 
that what was some years ago referred to as a homogeneous group of cells, is nowadays 
considered a collection of distinct subtypes of cells, characterized by a set of distinct markers.  
Concerning fibroblasts, candidate markers for these subtypes can be PDGF receptors and 
FAP, but many more are likely to be soon identified. An useful approach to clarify this issue 
is represented by new technologies such as CyTOF, in situ gene expression profiling and 
single cell RNA sequencing [168] [169]. Different subsets of cells can have different origins, 
and recent studies have addressed this question using the “lineage tracing” technique [170] 
[171]. The idea that tumor stroma is a heterogeneous and continuously changing pool of cells 
and matrix, is lately being supported by several publications suggesting the possibility that 
some kinds of stroma cells could work “against” cancer progression. This is true in particular 
for CAFs, pericytes and macrophages. In the first case, emerging evidences in pancreas 
tumour biology, view CAFs as protective against the tumoral development [172] [173], 
opposite to the old-fashioned view of  them as tumour promoting. 
About pericytes we have seen how different subtypes, in different tumours, can promote 
[103] or restrain tumour growth [104]. A similar process can happen within the same tumour 
at different developmental stages, for what concerns their activity in facilitating or inhibiting 
metastasis formation [106]. Recent evidences reveal that differential patterns of markers-
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expression can characterize, in breast cancer, different subtypes of pericytes potentially 
connected with different prognosis and sensitivity to therapy [174]. 
The diversity of tumour-associated macrophages has been widely explored in the previous 
chapter. Their polarization into different subsets exemplifies the plasticity of the immune 
microenvironment in relation to tumour development. 
These new findings show that tumour microenvironment might be composed of cells 
undergoing different functional switches during different steps of tumorigenesis. Our new 
challenge will be to characterize these components and turn our knowledge about their 
heterogeneity into a new therapeutic weapon. 
3. TUMOUR MICROENVIRONMENT IN OVARIAN 
CANCER 
3.1   INTRODUCTION 
The progression of tumour cells from transformation to invasion and metastasis, relies on the 
communication with the surrounding microenvironment. 
Ovarian stroma is a functional part of the organ and its role in the normal ovary is well 
established. The interstitial stroma supports and actively helps and triggers some of the stages 
of folliculogenesis, up to the ovulation stage [175]. For instance, molecules like BMP 4 and 
BMP 7 (members of TGF beta family factors), expressed by ovarian stromal cells have been 
implicated as positive regulators of the primordial to primary follicule transition [176] [177]. 
As in the normal organ, during tumorigenesis ovarian stroma deeply interacts with ovarian 
cancer cells through a synergistic paracrine communication involving several cell types and 
molecules. Although multiple cells are present in the ovarian tumour microenvironment, one 
of the principal actors dominating the intricate net of signals is represented by CAFs. Some 
studies have shown how the interaction between ovarian cancer cells and normal fibroblasts 
can activate the latter to CAFs. Yao et al in 2009 demonstrated that conditioned medium from 
SKOV3, an ovarian cancer cell line, is able to activate normal fibroblasts into -SMA 
expressing cancer associated ones, probably through secretion of a factor called chloride 
intracellular channel- like 4 (CLIC 4) [178]. Moreover, CAFs from ovarian cancer tissues 
have been proven to induce migration and invasion of ovarian cancer cells [179].  
Fibroblasts are not the only relevant components of ovarian tumour stroma, vessels, 
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inflammatory cells and ECM components interact to help tumour development and have been 
described as prognostic indicators [180] [181] [182]. The particular pattern of ovarian cancer 
metastatization mostly involves spreading in the peritoneal cavity. When ovarian cancer cells 
migrate around the peritoneal cavity, and it is still unclear if this route is chosen for a simple 
anatomical advantage or if factors secreted by peritoneal cells and cells of the omental tissues 
guide ovarian cancer cells through the metastatic process.  
There is a growing body of evidence that shows how cell-cell interaction via adhesion 
molecules and secreted factors are responsible for the homing of ovarian cancer cells through 
the peritoneal lining [183]. Mesothelial cells can help ovarian cancer cells and sustain them 
with growth factors such as VEGF and FGF2 [184]. In turn, epithelial ovarian cancer cells 
can condition mesothelial cells to promote adhesion and invasion through secretion of TGF 
beta and plasminogen activator inhibitor type I [185, 186]. 
 
 
Figure 3: Histology of serous ovarian cancer. Figure adapted from The Human Protein Atlas. 
3.2   STROMA-RELATED PROGNOSTIC FACTORS 
Lately, several studies addressed the issues of ovarian stroma compartment being related to 
prognosis in ovarian cancer patients. Labiche and colleagues, measuring the stroma 
compartment according to the collagen content, found a negative correlation between survival 
and amount of stroma in a subset of patients with epithelial ovarian cancer stage III and IV 
[187]. Moreover a recent study reported that Fibroblasts Activation Protein (FAP) expression 
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in stroma fibroblasts to be associated with worse overall survival and worse platinum 
response in a cohort of patients affected by epithelial ovarian cancer [188]. Following this 
path of investigation, Wimberger and colleagues found a positive association between 
expression of VEGFR 1 in primary ovarian cancer tissues, found mostly expressed in the 
vascular wall and across the stroma and decreased progression free survival, again confirming 
the common opinion that describes stroma and stroma related factors in ovarian cancer to be 
associated with a poor prognosis [189].  
An interesting recent study by the Australian Ovarian Cancer Study Group investigates the 
association of a pericytes score determined through gene expression data, with prognosis of 
ovarian cancer and found it related to poor survival in two independent databases. They 
confirmed their results in in vitro co-cultures, mouse xenografts and patients tissue 
microarrays expression of -SMA protein [109]. 
Recently a study from Horikawa and colleagues, analysed gene expression and protein 
expression of HGSOC and found that an up regulation of myeloid cells chemo attractants was 
present in cases where VEGF expression was high, and was associated to shorter survival A 
mouse model with MDSCs expressing VEGFR1 and 2 helped to understand that migration 
and differentiation of these cells were stimulated by VEGF, thus confirming the negative role 
of VEGF on prognosis of ovarian cancer [190] 
Microvessel density (MVD) was also studied in relation to tumor prognosis ovarian cancer. 
Nadkarni et al revealed the existence of a relationship between null mutation rate of p53 and 
high MVD, detected with CD31 staining, in patients affected by stage III and IV ovarian 
cancer. The association of high MVD and mutation of p53 was related to increased 
recurrence risk and worse overall survival [191]. Another study evaluated MVD using fully 
automatic image analysis, and found it to be an independent prognostic factor in advanced 
ovarian cancer patients [192]. 
One of the most important studies to show a contribution of the immune microenvironment in 
ovarian cancer was published in the New England Journal of Medicine and described a good 
prognostic effect of intra-tumoral T lymphocytes [124]. Immediately following was the 
discovery that PD-1/PD-L pathway, involved in the immunosuppressive response, is a 
prognostic factor for ovarian cancer [193]. Tumour- associated macrophages have not yet 
been deeply studied in ovarian cancer. A few findings associated them with good prognosis 
as described in paragraph 2.6. 
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3.3  STROMA-TARGETED THERAPIES  
Many of the new therapeutic approaches in ovarian cancer are addressed to tumour 
microenvironment and, involve the use of vascular endothelial growth factor (VEGF) 
pathway inhibitors (antibodies and small tyrosine kinase inhibitors), angiopoietin inhibitors, 
immune checkpoint inhibitors. 
Bevacizumab is an anti-VEGF antibody with antiangiogenic activity that has shown a gain in 
PFS when added to chemotherapy followed by maintenance in first line, but no overall 
survival (OS) gain [33].  However, in a subgroup analysis of the ICON 7 trial, the benefit of 
bevacizumab in terms of overall survival seems to be higher in patients with advanced 
disease and residual tumour after primary surgery (36.6 versus 28.8 months, HR 0.64, 95% 
CI 0.48-0.85) [34]. In both platinum sensitive relapse (OCEAN trial) and in platinum 
resistant relapse (AURELIA trial), adding bevacizumab to chemotherapy yielded an 
improved PFS [194] [195]. Bevacizumab is nowadays approved for the use in first line as 
well as for relapse of ovarian cancer. 
Other angiogenesis inhibitors are tested in clinical trials. One is the angiopoietin inhibitor is 
trebananib (AMG 386). In a phase III trial trebananib (TRINOVA-1 trial) plus paclitaxel 
treated patients experienced prolonged PFS [196].  
Pazopanib is a tyrosine kinase inhibitor that targets VEGFR-1, 2, 3, PDGFR  and , and c-
kit. In a phase III study, Pazopanib administered as maintenance after first line standard 
treatment and showed a gain in PFS of 4.6 months [197].  
Cediranib is a molecule targeting VEGFR 1, 2, 3 PDGFR and , FGFR and c-kit. A phase 
III study, ICON6, evaluated its efficacy in recurrent platinum-sensitive EOC, comparing 
cediranib+ platinum-based therapy and cediranib in maintenance, to platinum alone and 
cediranib+ platinum. The increase in PFS and OS for the treatment with maintenance 
cediranib to chemotherapy alone was of 3.2 and 2.7 months respectively [198]. 
There are recent efforts in investigating immune based therapy in ovarian cancer. The new 
strategy based on blocking the complex PD-PD-L1 with Nivolumab has been tested in phase 
II clinical trials and produced an ORR of 15% in ovarian cancer [199]. At an interim analyses 
of phase Ib clinical trials for the PD-L1 inhibitor avelumab and the PD-1 inhibitor 
pembrolizumab, generated interesting results as well (ORR of 10.7% and 11.5% respectively) 
[200]. Another PD-L1 inhibitor, adalimumab, is currently in clinical trials in ovarian cancer. 
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Adoptive transfer of tumour-infiltrating lymphocytes, as completion to the chemotherapy in 
adjuvant setting [201], and treatment with CTLA-4 antibody in advanced ovarian cancer have 
also reached significant results [202]. 
Another approach combining immune and angiogenic targeting is the use of coledronate, a 
bisphosphonate, in a mouse model of ovarian cancer. Coledronate inhibits secretion of 
angiogenic cytokines both from endothelial cells and macrophages, resulting in a significant 
reduction of tumour size [203]. 
The wide range of current and experimental treatments targeting tumour stroma in ovarian 
cancer is reviewed in [204]. 
These new therapeutic approaches in ovarian cancer show that tumour microenvironment has 
now become an established target for the treatment of patients affected by this malignancy. 
Despite that, resistance remains a huge problem that makes urgent on one hand the search for 
new biomarkers that identify subgroups with different prognosis and sensitivity, and on the 
other hand the discovery of new targetable molecules. 
3.4   STROMA-RELATED PREDICTIVE FACTORS  
Regarding therapy outcome, FAP expression in tumour stroma was reported to be 
significantly associated with shorter time to recurrence after platinum therapy in patients with 
epithelial ovarian cancer [188]. Establishing new biomarkers aimed at predicting response to 
anti-angiogenic therapies is a challenge in ovarian cancer research. Bevacizumab has shown a 
limited gain in survival and predictive markers of response may achieve optimization. The 
search for biomarkers predictive of response to anti-angiogenic therapies involves different 
kinds of tumours and so far has not produced any clinically validated factor. Several attempts 
have been made with the measurement of baseline plasma VEGF levels, that seem to be 
higher in patients responding to bevacizumab in gastric cancer [205]; baseline or treatment 
induced changes in plasma levels of PLGF and VEGFR2 in renal cancer [206] [207], breast 
cancer [208] and lung cancer [209]. Contrasting results have been achieved with the use of 
functional imaging to measure heterogeneity of tumour vascular enhancement [210], and 
some encouraging data were collected when measuring circulating endothelial cells before 
and after antiangiogenic therapy in colorectal and breast cancer [211] [212]. 
Worthy to be mentioned is the evidence in favour of an association between VEGF genetic 
polymorphisms and differences in overall survival in breast cancer patients undergoing 
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combinatory therapy with paclitaxel and bevacizumab (in particular the genotype VEGF-
2578 AA and the allele VEGF-1154 A with better prognosis) [213].
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4. AIMS OF THE THESIS 
The general aim of this thesis was to explore the composition of tumour microenvironment in 
serous ovarian cancer and identify its implications on survival and response to treatment. 
The specific aims were: 
1. To describe the biology of CAFs, vascular and perivascular cells and immune cells in the 
tumour microenvironment of serous ovarian cancer. 
2. To investigate the prognostic and predictive potential of CAFs, vascular and perivascular 
cells and immune cells in the tumour microenvironment of serous ovarian cancer. 
3. To compare the stromal, vascular and perivascular phenotype of serous ovarian cancer, to 
other selected tumour types 
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5. PATIENTS AND METHODS 
5.1 PATIENTS AND TUMOUR MATERIAL 
5.1.1 PAPER I-II AND III 
In paper I, II and III the same cohort of ovarian cancer patients was investigated. The 
cohort was composed by women diagnosed with ovarian cancer from1986 to 2006 at the 
Department of Gynaecologic Oncology, University Medical Centre Groningen (Groningen, 
The Netherlands). Of the total 355 patients, tumour material was collected. 186 patients 
(52%) were chemo-naive and diagnosed with serous histologic type, and were included in 
our study (Figure 4). Clinico-pathological data were retrieved from medical records. 
Staging was performed according to FIGO. Classification and the three-tier differentiation 
grading were performed according to World Health Organization standards at the time. 
For paper II and III only the subgroup of patients with tumor material derived from the 
primary ovarian site was considered for the analyses (N 138). 
All patients gave informed consent. Studies were conducted in accordance with the 
Declaration of Helsinki principles and Institutional review board policies at University 
Medical Center Groningen. The study was also approved from the regional ethical 
committee of Stockholm (Dnr 2016/551-32).  
Formalin-fixed and paraffin-embedded (FFPE) tissue blocks containing tumour in ovarian, 
omental and peripheral metastatic tissue and corresponding hematoxylin and eosin (H&E)-
stained slides were retrieved from the pathology archives. Tumour specimens were 
obtained from the primary ovarian site in 138 patients, and matched tissues from metastatic 
lesions were also obtained from 91 patients. In 48 of 186 patients tumour tissue was 
obtained from only the metastatic site. A pathologist selected tissue microarray (TMA) 
cores as representative tumour areas and four 0.6 mm2 core biopsies were taken from each 
tumour specimen and arrayed on a recipient paraffin block using a tissue microarrayer 
(Beecher Instruments, Silver Spring, MD). One to three tissue blocks per patient were 
available, taken from different tumour areas (primary site, omentum, peripheral metastasis). 
All arrayed samples were H&E stained to confirm the presence of tumour tissue.  
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Figure 4: Consortium diagram of the study population for paper I, II and III. 
5.1.2 PAPER IV AND V 
For paper IV and V the same cohort of patients was investigated. All patients, diagnosed 
between 2002-2006 in Stockholm County with ovarian cancer, fallopian tube, primary 
peritoneal carcinoma and undesignated primary site according to the Swedish cancer registry, 
were screened for eligibility. Inclusion criteria were age above 18 years; high-grade serous 
histology; FIGO stage IIC to IV; no administration of chemotherapy prior to surgery or 
diagnostic biopsy, and availability of tissue from the pre-chemo tumour. Exclusion criteria 
were history of previous neoplastic disease (except for in situ cancer or basalioma); diagnosis 
at autopsy; prior chemotherapy; if either surgery or diagnostic biopsy was not performed 
(only cytology based diagnosis). All cases were re-classified by a pathologist (specialized in 
gynaecology) from the older three-tier differentiation grade to the new two-tier grade system, 
and only high-grade serous tumours were selected.  
Tumor tissues collected 
from patients with ovarian 
cancer 1989-2006 (N= 355) 
Non available tissues 
Non chemo-naive patients 
(N= 34) 
Chemo naive patients with 
tumor tissue collected at 
primry debulking surgery 
(N=321) 
Non serous histologic type 
(N=135) 
Serous histologic type 
(N=186) 
Tissues from primary 
ovarian tumor (N=138) 
Tissues from metastatic 
lesions only(N=48) 
Tissues from primary tumor 
only(N=47) 
Tissues from primary tumor 
and matched metastatic 
lesion (N=91) 
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Of the 401 screened for eligibility, 199 patients met the including criteria, of which 32 did not 
have available tissue and 31 missed histology data verification or clinical data, thus 136 
patients were included in the study (Figure 5).  Only patients with available tissue from 
adnexal site were included in the analysis (N=116, Table 1) since stroma markers vary 
somewhat in different anatomical sites. The FIGO stage was classified according to the 1988 
system [214]. Clinical data were retrieved from the charts, coded, and collected in case report 
files. Response was performed according to the Gynecological Cancer Intergroup (GICG) 
criteria [215].  The Regional Ethics Committee approved of the study (ethical permit number 
2012/539-31/1).  
FFPE biopsies and sections stained with hematoxylin and eosin were retrieved from tumour 
tissues obtained at primary surgery or diagnostic biopsies derived from chemo-naive patients. 
Sections were reviewed and a gynaecological pathologist confirmed diagnosis. 
Representative areas of the tumour were marked on the slide and from the corresponding 
blocks a punch of 1 mm diameter was cut and a TMA was built. Two punches per patients 
were taken, in line with the rules for TMA building at Karolinska University Hospital; if 
possible, one punch was retrieved from the primary site, and one from the metastatic 
omentum or peritoneum.  
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Figure 5: Consortium diagram for study population of paper IV and V. 
5.2 METHODS: IMMUNOHISTOCHEMISTRY  
5.2.1 PAPER I, II AND III 
Primary antibodies used were recognizing α-SMA (anti human Smooth Muscle Actin, code 
M0851, Clone 1A4; Dako, Inc., Denmark (dilution 1:300)), PDGFR  (PDGF Receptor 
beta 28E1 Rabbit mAb, 3169, Cell Signalling Technology, Danvers, MA (dilution 1:70)) 
and Desmin (Rabbit Anti-Human Desmin code HPA 018803-100UL Sigma Life Sciences, 
St Louis, MO (dilution 1:500)). Slides underwent treatment with secondary anti- mouse or 
anti-rabbit antibody (ImmPRESSTM-AP Polymer Anti-Mouse IgG, MP-5402 and 
ImmPRESSTM-AP Polymer Anti-Rabbit IgG MP-5401, Vector Laboratories, Burlingame, 
CA) and developed with Vector Blue AP substrate Kit (SK-5300, Vector Laboratories, 
Burlingame, CA). Sections were then incubated with primary antibody against CD34 
M7165 Mouse mAb, DAKO, DAKO Agilent Technologies, Santa Clara, United States 
(dilution 1:100)) for 1 hour at room temperature, followed by ImmPRESS-AP Alkaline 
Phosphatase Polymer Anti-Mouse Kit at room temperature in a humidity chamber and 
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developed with Vector Red AP substrate Kit (SK-5100, Vector Laboratories, Burlingame, 
CA). (For details see [112] [113] and PAPER III in PAPERS section). 
5.2.2 PAPER IV 
Immunohistochemistry for FAP (rat antibody against human FAP 1:200, MABS1001, 
Vitatex, Stony Brook, NY) was performed following a VENTANA-ROCHE protocol and 
relative reagents. After deparaffinization slides underwent cell conditioning with Conditioner 
#1, Mild CC1, and Standard CC1. Then they were stained with primary and secondary 
antibodies, and treated with Ultramap anti Rt-HRP. After that tissues were counterstained 
with hematoxylin II and post counterstained with bluing reagent. An additional 
counterstaining with hematoxylin (Mayers HTX, 01820, Histolab, Sweden) was then 
performed manually. 
Immunohistochemistry for CD8 (1:100, M7103, DAKO Agilent Technologies, Santa Clara 
CA) was performed following a VENTANA protocol and relative reagents. After 
deparaffinization slides underwent cell conditioning with Conditioner #1, Mild CC1, 
Standard CC1 and Extended CC1. Then primary antibody and OMap anti-Rb HRP were 
applied. Counterstaining with Hematoxilin II and post counterstaining with bluing reagent 
were done and an additional counterstaining with hematoxylin (Mayers HTX, 01820, 
Histolab, Sweden) was performed manually. 
5.2.3 PAPER V 
Single stainings for CD11c, CD80, CD163, FAP and CD8 were performed as follows: 
sections were deparaffinized, rehydrated and boiled at 110
o 
C for five minutes in deckloaking 
chamber with a pH 6 Buffer solution. Treatment in 3% H2O2 for 20 minutes was performed 
and after blocking with blocking solution (DAKO) slides were incubated with primary 
antibodies over-night at 4
o 
C. The antibodies used were 1:100 dilution of NCL-L-CD11c-563 
Mouse IgG2a; Leica BioSystems (CD11c), 1:100 dilution of NCL-CD163 Mouse IgG1, 
Leica BioSystems (CD163) and 10 g/ml of Monoclonal Mouse IgG1 Clone # 3771 MAB 
140; Biotechne (CD80). 
Sections were incubated with EnVision HRP anti-mouse kit (DAKO Agilent Technologies, 
Santa Clara, United States) for anti CD11c and anti Cd163 stainings, and with ImPRESS 
antimouse Ig Vector (MP 7402, VECTOR, Burlingame CA, 9410) washed and developed 
with DAB (3,3'-diaminobenzidine). A final counterstaining with Hematoxylin (Mayers HTX, 
01820, Histolab, Sweden) was performed before mounting. 
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Procedures for staining of FAP (fibroblast activation protein) and CD8 have been described 
for paper IV.  
Procedures for double staining with PDGFR -, desmin- or α-SMA-antibodies together with 
CD34 antibodies were similar to the ones described earlier for paper I, II and III [113] [112]. 
For double stainings with CD11c, CD80 or CD163 plus CD34 antibodies, the tissue was 
treated with the primary anti-macrophage antibodies described above, then washed and 
stained with VECTOR Blue Alkaline Phosphatase substrate Kit. Second treatment with anti-
CD34 was performed as described earlier [113], liquid paramount RED from DAKO (K0640 
DAKO Agilent Technologies, Santa Clara, United States) was used to develop CD34 
staining. 
Slides were subsequently scanned with Aperio Scanscope AT, and acquired through Image 
Scope for visualization. 
Establishment work for the single and double staining procedures for CD11c, CD80, CD163 
and CD68 were performed on some paraffin embedded whole section slides derived from a 
prospectively collected cohort of high-grade ovarian patients, approved by The Regional 
Ethics Committee of Karolinska Institute (ethical permit number 2012/596-31/4).  
5.3 METHODS: DIGITAL AND MANUAL IMAGE ANALYSES  
5.3.1 PAPER I 
The double stained slides were scanned and, after quality selection, images were analysed 
using Image J software, with an algorithm developed in-house. CD34 staining was used to 
determine vessel density, mean vessel area and mean vessel perimeter. For perivascular-
restricted measurements the areas surrounding the vasculature were analysed. Analyses of 
desmin-, PDGFR - and α-SMA- stained samples yielded information about average 
intensity of the staining with these three markers in the perivascular area (perivascular 
intensity). To obtain values for perivascular fraction, individual vessels were classified as 
‘uncovered’ or ‘covered’ and ratio of covered vessels over total vessels per case was 
thereafter calculated, to yield the perivascular fraction metric. PDGFR - and α-SMA-
staining were also used to determine the stroma fraction, defined as the fraction of total 
tumor area positive for these markers. The stroma fraction was calculated as the sum of all 
positive regions divided by the total tumor area. In the case of PDGFR analyses this step 
also included exclusion of 35 cores with positive epithelial staining. Finally, PDGFR and 
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α-SMA-staining were used to obtain values for PDGFR - and α-SMA - intensity (stroma 
intensity) by calculating the average intensity of PDGFR - and α-SMA-staining in the 
marker- positive area.  
Together these analyses, performed on the CD34/ α-SMA, CD34/desmin and 
CD34/PDGFR -staining yielded quantitative data for 13 different stroma-related metrics. 
For details see [113]. 
5.3.2 PAPER II 
The scanned double stained slides used for study I underwent, after quality selection, image 
analysis using Image J software, with an algorithm developed in-house (R 3.2.2 GUI 1.66 
Mavericks build (6996) http://www.R-project.org).  
CD34 staining was used to determine vessel density, median vessel diameter and median 
vessel area. Perivascular intensity (PVI) was defined as median optical density (OD) of the 
perivascular staining.  
To measure the heterogeneity of PDGFR within each tumor, the inter-quartile range of all 
vessels in each tumor was calculated (IQR). For detail see [112]. 
5.3.3 PAPER III 
The scanned double stained slides used for paper I underwent, after quality selection, image 
analysis using Image J software [112]. 
Vascular and perivascular stainings were evaluated as described above and in [112]. 
 Marker-positive stroma area was defined as the area of the analysed sample, having 
expression of the marker over a pre-defined baseline level; the perivascular regions (defined 
as above) and vessel regions were excluded from the marker-positive stroma area. Marker-
positive stroma fraction was defined as ratio between marker-positive area and total analysed 
sample area. Marker-positive stroma intensity was defined as median of the pixels intensity 
of marker staining inside marker-positive stroma area. 
The list of such metrics for every individual vessel in each sample was collected. A case-
based median of these values was calculated. To quantitate the heterogeneity of the 
distribution of the vessels in the sample, the difference between 1
st
 and 3
rd
 quartile was 
calculated in each case - inter-quartile range (IQR), yielding case-based value for the metric 
“vessel distance IQR”.   
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5.3.4 PAPER IV 
For FAP scoring, slides were reviewed separately by a pathologist and an oncologist. Only 
cases with availability of tumour material from adnexal site were considered for the analyses 
(all cases of undesignated site and primary peritoneal cancer were spread to the adnexa). FAP 
fraction positive stroma on total stroma and FAP intensity of positive stained stroma, were 
scored independently on a semi quantitative scale and a consensus was found between the 
two observers. FAP fraction was scored on a 5 points scale (0: 0% of stroma area stained by 
FAP, 1: 1-10%, 2: 11-50%, 3: 51-95%, 4: 96-100%) and FAP intensity was scored on an 
optical 4 points scale (0 to 3); descriptive images are provided in Figure 2. Two metrics were 
then produced: FAP positive fraction in the primary tissue and FAP intensity in the primary 
tissue. For the survival analyses FAP positive stroma intensity was dichotomized in low 
(score 0 and 1) and high (score 2 and 3).  
CD8 density was scored by an oncologist on a semi-quantitative five points scale (0: 0% of 
stroma area covered by CD8 positive cells, 1: 1-10%, 2: 11-50%, 3: 51-95%, 4: 96-100%), as 
CD8 density in the epithelial areas of the primary tissue and CD8 density in the stromal areas 
of the primary tissue (Fig. 3). Grade 4 was never reached in stromal CD8 density scoring, so 
for survival analyses CD8 stromal density was used as dichotomized in low (score 0 and 1) 
and high (score 2 and 3). A similar scoring procedure is used by Donnen et al [216]; in our 
analysis, high density of CD8 scoring coincides with theirs, while our definition of low 
density corresponds to low and intermediate in their cohort. 
5.3.5 PAPER V 
For the macrophage single stainings markers density was scored on a semi-quantitative five-
point density scale (0: absent staining; 1: 1-10% positivity, 2: 11-50% positivity, 3: 51-95% 
positivity; 4: 96-100% positivity) separately in histo-morphologically defined tumour 
epithelial and tumour stromal areas. 
Procedures for staining and scoring of FAP (fibroblast activation protein) and CD8 have been 
described earlier for paper IV. Algorithms developed in-house were used for double stainings 
of PDGFR, desmin and α-SMA plus CD34 as described in paper II and III. 
For the macrophage double-stainings images were analysed with Image J software.  Digital-
image analyses of the double staining with either CD11c, CD80 or 163 antibodies together 
with CD34 antibodies was used to collect three “metrics” for each of the macrophage-related 
markers. “Total tumour density” was determined by calculating the fraction of total “region 
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of interest” that was positive for marker. Two metrics were collected related to marker 
density in perivascular areas; “perivascular area 1 density” and “perivascular area 2 density” 
(see also schematic Supp. Fig. 1). Perivascular area 1 was defined as the area most close to 
CD34 positive regions extending 30 pixels away from the CD34 positive area. Perivascular 
area 2 was defined as the area surrounding perivascular area 1 and extending 30 pixels 
peripheral of perivascular area 1 (two pixels corresponding to one micrometre). 
“Perivascular area 1 density” and “perivascular area 2 density” were determined by 
calculating, for each case, the fraction of marker-positive area in all summed-up perivascular 
areas 1 and 2, respectively. Marker positive area is defined as the area where the intensity of 
the marker is above a threshold defined at a preliminary visual evaluation.  
Validity of the automated scoring was tested by comparing correlations between manually 
scored and digitally scored perivascular density area 1 and total density from 30 selected 
cases of CD80/CD34 double-stainings. As shown in Supp. Table 1, correlation coefficients 
were overall high with Goodman and Kruskal´s gamma index values of 0.9 and 0.8 
respectively.  
5.4 METHODS: STATISTICAL ANALYSES 
5.4.1 PAPER I AND II 
The Spearman two-tailed test was used for correlation estimation between stromal markers 
expression, a correlation coefficient of 0.5 and a p- value <0.01 were used as reference 
threshold values. Cox proportional hazards model and the Kaplan-Meier estimator were 
used to analyse the association between the markers and overall survival (OS). Kaplan-
Meier survival analysis was used to analyse survival rates and a multivariate Cox regression 
model was used to calculate hazard ratios of the clinical-pathological factors and the stroma 
related metrics for patients’ survival and to determine their independence. The survival 
findings were confirmed by backward selection. Associations between stroma metrics and 
clinico-pathological characteristics of the patients were performed with Chi-square test. All 
tests were done at the 95% significance level and were performed using SPSS version 22 
(SPSS Inc., Chicago, IL). Forest Plot was done using R 3.2.2. Meta package.  
5.4.2 PAPER III 
For comparison between tumour types for marker-intensity-related metrics, original data for 
each tumour type was normalized and given values between 0 and 1. Normalization was done 
case-wise for stroma intensity and vessel-wise for perivascular status. Normalization 
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addressed the issue of skewed distribution of data by skewness adjustment as described by 
Vanderviere [217] and vessel distance IQR” metrics were dichotomized per the median. 
All tests were done at the 95% statistical significance level and were performed using SPSS 
version 22 and 23 (SPSS Inc., Chicago, IL) and Rstudio (Version 0.99.489 – © 2009-2015 
RStudio, Inc.). Differences between tumour types regarding case-based values for stroma 
metrics, were determined using Mann-Whitney U test. Correlations between case-based 
stroma metrics, as analysed in Fig. 2, were determined by Spearman correlation test for the 
pair-wise analyses.  Log Rank Tests and Cox Regression Models were used to estimate 
relationships between analysed metrics and overall survival. Associations with the clinico-
pathological characteristics were evaluated with Pearson´s Chi Square test. 
5.4.3 PAPER IV AND V 
Spearman correlation test and Goodman and Kruskal’s Gamma correlation test determined 
correlations between case-based stroma metrics.  Comparisons of means were performed 
through Wilcoxon test, Pearson Chi-square test and Mann-Whitney test. 
Overall survival (OS) was defined as survival from date of diagnosis to date of death of any 
cause. Progression- free survival (PFS) was defined as the time frame from the date of 
diagnosis to progression, recurrence or death from any cause (whichever came first). 
Objective response rate (ORR) was defined as the proportion of patients with a response at 
the end of treatment (EOT): a partial regression or complete regression (PR and CR) was 
considered response, while stable disease and progression of disease (SD and PD) were 
considered as absence of response.  Significant differences in OS and in PFS were estimated 
using Log Rank tests and Cox Regression proportional hazard models. All variables showing 
a significant p value (< 0.05) at the univariate analysis were entered into the multivariate 
model. FIGO stage, age at diagnosis and residual tumour after primary surgery (if applicable) 
were the clinical variables included in the multivariate Cox regression model. Correlation 
analyses were performed through Pearson Chi-square test. All statistics were performed in 
SPSS, version 23.0. 
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6. RESULTS AND DISCUSSION 
6.1 VASCULAR AND PERIVASCULAR CHARACTERISTICS 
6.1.1 VASCULAR AND PERIVASCULAR BIOLOGY IN SEROUS OVARIAN 
CANCER 
In the first two studies (PAPER I and II) we analysed perivascular and vascular features of 
serous ovarian cancer, and investigated the presence of prognostic markers related to tumour 
microenvironment. 
A notable observation from the investigation of vessel features (as vessel density, lumen area 
and lumen perimeter) and perivascular features (as coverage with desmin, α-SMA and 
PDGFR), was the total absence of correlations between these two groups of features. This 
might suggest an independent regulation, during vessel maturation, of features strictly related 
to endothelial cells from the ones related to perivascular cells. A significant correlation lacked 
also among the three subtypes of pericytes, suggesting again the existence of different 
regulatory circuits controlling subtypes of pericytes with different functions. When 
comparing these two entities in primary ovarian tissues and matched omentum metastases, 
we found, again, no significant correlation, with the exception of PDGFR perivascular 
intensity. This intra-patient heterogeneity may be important to be taken into account when 
considering anti-angiogenic approaches in patients with advanced and metastatic tumours. 
6.1.2   PROGNOSTIC SIGNIFICANCE 
When analysing the potential impact of perivascular metrics on survival of serous ovarian 
cancer we found that high PDGFR positive perivascular intensity (PAPER I) and high 
heterogeneity of PDGFR perivascular intensity, defined by the interquartile range of the 
marker-intensity (PAPER II), were related to worse prognosis (figure 6B and figure 7).  
Recent evidences reporting an interaction between pericytes and macrophages in promoting 
metastatization through a PDGF-BB related pathway [107] support our finding of a 
particular subset of perivascular cells impacting on survival. 
In ovarian cancer, characterization of perivascular cells may have a double role: on one hand 
it can be used as a way to stratify patients undergoing anti-angiogenic therapies [218] on the 
other it can help to improve these treatments implementing them with a pericytes-targeted 
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approach. Dual targeting with VEGF and PDGF blockade has indeed generated interesting 
results in vitro and in vivo in this malignancy [219] [220].     
According to our data, heterogeneity of perivascular coverage seems to impact negatively on 
prognosis (PAPER II). It is known that tumour cells intra-patient heterogeneity is a driver for 
adverse clinical outcome [221], our study, though, points out at the perivascular 
heterogeneity as a marker or driver for cancer aggressivity. Perivascular heterogeneity can 
indicate the presence of vessels in different stages of maturation, which might cause non-
homogeneous tumor vascularization and oxygenation, fuelling in tumor cells the shift 
towards more aggressive phenotypes [95]. This process makes “vessel normalization” a 
desirable target of cancer therapy. As suggested by our findings, in serous ovarian cancer, 
vessel normalization needs to be achieved implementing control of perivascular cells together 
with endothelial cells. Therefore, the results of our first two articles prompt new studies 
supporting the role of perivascular cells and PDGFR, as prognostic factors and molecular 
targets for ovarian cancer therapy. 
Notably, neither vessel density nor vessel diameter, were related with overall survival in this 
cohort of patients. 
 
 
 
Figure 6 A: Survival curves for high and low PDGFβR positive stroma fraction. 
Kaplan-Meier graph shows worse overall survival for high PDGFβR positive stroma fraction as compared to low 
PDGFβR positive stroma fraction in serous ovarian cancer (n=186 patients) (p= 0.01 2, Log Rank).  
Figure 6 B: Survival curves for high and low PDGFβR positive perivascular intensity.  Kaplan-Meier graph 
shows worse overall survival for high PDGFβR positive perivascular intensity as compared to low PDGF βR 
positive perivascular intensity, i n 186 patients  (p= 0.005, Log Rank).  
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Figure 7: Survival curves for high and low PDGFR positive perivascular intensity IQR. Kaplan-Meier 
graph shows worse overall survival for high PDGFRβ positive perivascular intensity IQR as compared to low 
PDGFRβ positive perivascular intensity IQR, in 138 patients (p= 0.004, Log Rank). 
 
6.2   CAFs 
6.2.1 CAFs IN SEROUS OVARIAN CANCER 
In PAPER I and IV, we describe different subtypes of cancer-associated fibroblasts, 
composing the stroma, of serous ovarian cancer. In PAPER I we analyse two subtypes, the α-
SMA positive ones and the PDGFR positive ones; in PAPER IV we focus instead on FAP+ 
fibroblasts.  
In the first study, we notice an independence of the two cell subsets from each other, 
confirming once again the existence of different classes of tumour-associated stroma cells, 
previously reported by others [73] [222]. We also noticed a significant correlation between 
perivascular cells and fibroblasts both positive to PDGFR or α-SMA.  These data suggest 
a shared origin for perivascular cells and stroma fibroblasts. Some lineage tracing 
experiments on fibrosis and brain scarring, have indeed implied a perivascular cell of origin 
for interstitial fibroblasts and glial cells [223] [170]. When we compared primary sites and 
matched metastatic sites, we found a discordance of most of the stroma parameters, as we 
previously reported about vascular and perivascular features. This finding is in line with 
what has previously been reported for breast and colon cancer [224]. 
A third CAFs subtype is described in PAPER IV, the FAP+ subtype. The FAP protein 
seems to be exclusively expressed by fibroblasts (differently than PDGFR which might be 
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found in tumour cells as well) with a high inter-case variability, regarding both intensity and 
percentage positive of the stroma area.  
6.2.2 PROGNOSTIC SIGNIFICANCE 
In PAPER I we investigated the prognostic impact of the stroma-related metrics and 
revealed the presence of a significantly poor survival associated to high PDGFR stroma 
fraction, both in uni- and multi-variate analyses (figure 6A). Data on the negative impact of 
PDGFR positive stroma on survival, has previously been reported for breast and prostate 
cancer [72] [69]. Our group has recently shown with in vitro and in vivo studies, an increase 
in invasiveness and metastatization of colorectal cancer cells when cultured with PDGFR-
activated fibroblasts [225].  
FAP expressing cells instead, as analysed in PAPER I, did not show any impact on 
prognosis in the cohort of high-grade serous patients. 
6.2.3 PREDICTIVE SIGNIFICANCE 
The patient cohort available for PAPER I did not allow us to analyse the predictive value of 
the examined markers, due to lack of specific data on treatment. However, in PAPER IV we 
had a cohort of high-grade serous ovarian cancer patients where detailed clinical and 
treatment data was collected. Therefore, we could explore the potential impact of FAP+ 
CAFs on response to platinum-based treatments. We found on the cohort of patients with 
high density of stromal CD8+ cells and high intensity of FAP+ stroma cells to be associated 
with early relapse (<6 months after last platinum treatment, platinum-resistant) compared to 
low intensity of FAP (p=0.04). In the “high-density” CD8 group had also a shorter 
progression-free survival (PFS) in patients with high intensity FAP positive stroma, as 
compared to the group with low intensity FAP+ stroma (figure 8).  
Several in vivo and in vitro tumour biology studies have supported the existence of an 
immune-modulating effect for FAP+ fibroblasts [55] [139]; both these studies show that 
FAP+ CAFs interfere with the immune control of tumours, mostly interacting with T-
lymphocytes. In our analyses the modulatory effect of FAP+ cells, on sensitivity to therapy is 
detectable when there is a high immune control of the disease, expressed by density of T+ 
cells. 
Immunogenic cell death is a mechanism involved in the tumoricidal effect of platinum 
compounds, and it is triggered by different biological events sequential to the activity of the 
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chemotherapeutic agents on the tumoral cells [226] [227]. Our work suggests that 
immunogenic cell death, as a result of carboplatin treatment of high-grade serous ovarian 
cancer, undergoes modulating by of FAP+ fibroblasts. 
Clinical trial on immune-targeting in ovarian cancer, supported by the evidence that 
infiltrating T cells confer a good prognosis [124], are ongoing with alternating results [199]. 
Inhibition or depletion of FAP+ fibroblasts, may improve the outcome, conferring an 
advantage in cases in which FAP positive stroma cells weaken immune activation. Although 
the results need indeed to be validated in an independent cohort, FAP may be a targetable 
molecule to enhance sensitivity to therapy in patients with a strong CD8 immune response. 
 
 
 
Figure 8: Progression-free survival curves for high and low stromal FAP intensity among patients with 
measurable diseases at start of platinum-based chemotherapy in high-grade serous ovarian cancer (N=73).  
Log-rank test (p 0.01) showed a shorter PFS in patients with FAP high intensity as compared to FAP low intensity 
in the sub-population of patients with high CD8 stromal density  
!
FAP$in$CD8$low$
High!stromal!FAP!
intensity!
Low!stromal!FAP!
intensity!
P=0.01 
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6.3   MACROPHAGES  
6.3.1 MACROPHAGES DISTRIBUTION IN HGSOC, AND INTERACTIONS 
WITH TME 
Functionally distinct macrophage subsets exist in the tumour microenvironment and are 
characterized by specific markers expression and compartment-related regulatory functions. 
In PAPER V we investigated this subject, by profiling CD68 positive subtypes of cells, 
according to their expression of CD11c, CD80 and CD163 respectively; density was 
evaluated in the total tumor and in four different tumour compartments in a clinically well-
annotated cohort of high-grade serous ovarian cancer. 
 
CD163-positve cells were the most abundant among the marker-defined cell subsets. CD11c 
and CD163 subsets were strongly correlated to each other in tumour stroma and tumour 
epithelial areas, whereas CD80/CD163 in tumour epithelial areas and CD11c/CD80 in the 
perivascular areas showed the lowest correlations.  
 
When associations with other stroma features were explored, a negative correlation was 
detected between perivascular desmin-expression and perivascular CD163 cells, suggesting a 
displacement operated by this macrophage subtype, usually recognized as “M2”, towards 
pericytes in the vessel walls. A role of M2 macrophages in regulation of permeability enacted 
through physical contact between macrophages and endothelial wall has been recently 
described [228]. Positive significant correlations were observed between FAP+ fibroblasts 
and density of stromal CD11c and CD163+ cells, while absent or very low correlation was 
found with the other subtypes of stroma fibroblasts, again underlining the immune-related 
role of FAP+ cells. Significant positive associations were also revealed between stromal 
density of the CD8+ T cells and stromal density of CD11c, Cd80 and Cd163 positive cell 
subsets. 
6.3.2 PROGNOSTIC SIGNIFICANCE 
Despite the solid evidence that HGSOC maturates and disseminates in a stroma-rich 
environment highly populated by macrophages, the prognostic implications of these cell 
types have been poorly explored. Our analyses of overall survival identified that patients with 
high stromal CD11c density had a better prognosis as compared to patients with low CD11c 
stromal density (figure 9).  
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The association of CD11c positive cells with reduced tumour aggressivity, which translates 
into a better survival, might be explained considering their active bidirectional 
communication with Th1 cells [229]. Nonetheless the stromal restriction of the signal 
suggests the possibility of an interaction between CD11c-postive cells and CAFs, which are 
the dominating cell type of the ovarian tumour stroma. Findings from recent years have 
postulated the existence of functionally distinct CAF subsets with anti- or pro-tumoral effects 
[230] [231] [232] [233]. Some studies have also reported functionally relevant interactions 
between macrophages and CAFs [234, 235]. The possibilities that CD11c-positive 
macrophages exert inhibitory effects on pro-tumoral CAFs, or stimulate anti-tumoral CAF 
subsets, should therefore be further explored. 
 
 
6.3.3 PREDICTIVE SIGNIFICANCE 
When investigating relationships between markers and response to treatment we identified a 
possible association between perivascular CD80-positive cells and better response to 
platinum treatment (figure 10), an effect that seemed even clearer in patients with measurable 
disease at start of primary platinum-based treatment (PAPER V).  
CD80 is a co-stimulatory molecule, whose expression is necessary for the activation of Th1 
cells and it´s triggered by inflammatory stimuli [236]. The particular association with 
response to treatment suggests possible effects of CD80-positive cells on drug delivery. 
Moreover, we found no correlation between CD80-positive expression and vessel density, 
indicating effects on quality and maturation rather than quantity of vessels. Vessel-
normalizing functions of macrophages have indeed been suggested by previous studies. 
Wenes et al. recently demonstrated that macrophages could promote the formation of stable 
and functional vessels, though mechanisms involving activation of mTOR [237]. 
Furthermore, macrophage-induced normalization of tumour vasculature has also been shown 
to occur through down-regulation of PlGF [238].  
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Figure 9: Overall survival according to CD11c tumor stromal density among patients operated for high-
grade serous ovarian cancer.  
Log-rank test (p-value) showed that patients with high CD11c stromal density had a longer OS as compared 
patients with low CD11c stromal density. 
 
 
 
 
 
 
Time (months) 
_ low CD11c stromal density 
_ high CD11c stromal density 
 
p= 0.002 
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Figure 10: Progression-free survival (PFS) among patients with measurable diseases at start of platinum-
based chemotherapy in high-grade serous ovarian cancer according to fraction perivascular (PV) CD80 
positive cells in the A2 area (A2%).  
Log-rank test (p-value) showed that patients with high CD80 fraction of cells in the A2 area had a longer PFS as 
compared patients with low CD80 fraction of cells in the A2 area. 
 
 
6.4 COMPARATIVE ANALYSES OF TME IN OVARIAN, RENAL AND 
COLORECTAL CANCERS 
6.4.1 SIMILARITIES AND DIFFERENCES  
In paper III we aimed at studying the composition of tumor microenvironment in serous 
ovarian cancer, as compared to renal cell and colorectal cancer, through the investigation of 
several vascular, stroma and perivascular features, mostly related to PDGFR. 
Firstly, we investigated if the three tumor types demonstrate significant differences regarding 
features such as vessel diameter, vessel density and distribution, perivascular and stromal 
PDGFR expression. Secondly, analyses of the cohorts were used to explore the prognostic 
significance of a novel vascular metric, “vessel distance inter-quartile range (IQR)”, 
describing the intra-case heterogeneity regarding vessel distribution.  
Time (months) 
_ low CD80 PV-A2 
_ high CD80 PV-A2 
 
p=0.001 
 
 
 
   53 
 
The comparisons between the three tumor types demonstrated a set of differences. Vessel 
density of renal cell cancer was significantly higher than in colorectal and ovarian cancer. 
Vessel size was highest in ovarian cancer, while PDGFR positive stroma abundance was 
higher in colorectal cancer. Concerning perivascular status, colorectal cancer displayed 
higher levels of perivascular PDGFR expression than the other two tumor types. Intra-case 
heterogeneity of perivascular PDGFR expression was also highest in colorectal cancer.  
 
High “vessel distance IQR” was significantly associated with poor survival in both renal cell 
cancer and colorectal cancer (figure 11). 
 
 
 
Figure 11: Survival curves for high and low IQR of vessel distances in CRC, RCC and OC. Kaplan-Meier 
graph shows worse overall survival for high IQR of vessel distances in RCC and CRC, as compared to low IQR 
of vessel distances. 
 
6.4.2 DEFINITION OF DIFFERENT “PHENOTYPES” 
This study suggests that ovarian, renal and colorectal cancer display specific  
“vascular/perivascular” and “tumor/vessel”-“stroma/vessel” configurations, potentially 
related to their sensitivity to anti-angiogenic therapies.  
Renal cell cancer shows a phenotype with high vascularization and low perivascular 
coverage, possibly related to a VEGF-dependent and endothelial cells-dependent angiogenic 
program, as sustained by previous evidences [82, 239].  
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Studies by Smith et al [240] identified two tumor vascular phenotypes referred a “tumor-
vessel” phenotype with vessels distributed predominantly in tumor cells-rich areas and a 
“stroma-vessel” phenotype with vessels in stroma fibroblasts rich-areas.  Based on analyses 
of experimental cancer models, the study concluded that these two vessel phenotypes were 
linked to anti-VEGF sensitivity such that the “tumor vessel”-phenotype was more sensitive. 
Our analyses of stroma phenotypes of the three tumor types, and their known sensitivity to 
anti-VEGF-treatment are compatible with the concept proposed by Smith et al.  
Renal cell cancer displays a “tumor-vessel” phenotype and also high sensitivity to anti-
angiogenic drugs like bevacizumab, sunitinib and pazopanib [241] [242]. Ovarian cancer is 
characterized by a “tumor/vessel” configuration but also by moderate/high vessel maturation.  
This combination might underlie its partial sensitivity to anti-angiogenic therapy, mostly in 
combination with chemotherapy, but also as maintenance in mono-treatment, [33, 34]. 
Colorectal cancer instead has a phenotype with fewer and highly covered vessels immersed in 
a rich stroma (“stroma/vessel” phenotype), which could be the cause of the lower sensitivity 
to mono-treatment with antiangiogenic drugs [243, 244]. 
The phenotype patterns identified in these analyses require further validation. Their 
functional associations should also be experimentally tested. Potentially they can be used as 
signature to identify cases in ovarian or colorectal cancer associated with higher sensitivity 
to anti-angiogenic therapies.  Furthermore, it could be tested whether the anti-VEGF-
benefit in ovarian cancer is particularly strong in cases displaying the most typical 
“perivascular-low” phenotype. 
 
7. LIMITATIONS 
Throughout the different studies and in all the five papers we used two tumour collections 
both arranged as tumour microarrays (TMA). Despite the several advantages that this method 
has, such as availability of a large number of tissues with the smallest amount of resources 
needed to store and analyse them, plus the reduction in inter-cases analyses differences 
thanks to the arraying feature, the availability of a small area of tumour and of a restricted 
number of punches can sometimes limit the possibilities of catching tumour related 
heterogeneity. 
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In paper I, II and III we had access to a TMA consisting of up to four cores per tissue, but in 
study IV and V due to regulations of the pathology department we could get just one punch 
per tissue block.  
Therefore, we performed a quality analysis to check if the afore mentioned four cores were 
concordant for FAP scoring, allowing us to draw proper conclusions using our TMA with just 
one punch per patient. Staining and scoring techniques of the “four cores-TMA” were the 
same as for the “one core-TMA”. Just in ten out of 40 cases, one core of the four stained, was 
discordantly scored.  
For four of the five studies, we extensively used digital image analysis, which is often 
questioned for its adherence to visual scoring. We addressed this issue in paper V, where we 
showed that concordance between manual and digital scoring for 30 cases of the cohort used 
in the same paper, stained with CD80/CD34. The correlations between manual and digital 
scoring were quite high, with coefficients of 0.8 for the scoring of total area and of 0.9 for the 
scoring perivascular area (Kruskall and Goodman Gamma test). 
Regarding the patient selection, in paper I, II and III we used a cohort composed of cases of 
serous ovarian cancer not subjected to the two-tier grading system that now is used to grade 
ovarian cancer. Furthermore, patients were included starting from thirty years ago, which 
translates into a significantly different therapeutic approach, for example the surgical one. 
Despite that, for the same reason, we could benefit from a long follow up time, which was 
strength-point in our survival analyses. 
The biggest limitation of our five studies is represented by the lack of functional 
investigations. Nonetheless our evidences generated several mechanistic speculations that 
could lead in vitro and in vivo experiments. 
Despite the presence of some limitations that we tried to overcome, our studies could benefit 
of well-selected tumor material, detailed annotated clinical information and pathology 
revision (for IV and V), and deeply established laboratory techniques.  
8. CONCLUSIONS AND FUTURE PERSPECTIVES 
In our five studies, we characterized the tumour microenvironment of serous ovarian cancer, 
with the aim of identifying tumor-type-specific properties and to identify  factors impacting 
on prognosis and sensitivity to therapy. 
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We described serous ovarian cancer according to quality and quantity of its vasculature, 
perivascular coverage, composition in stroma fibroblasts, and in macrophages, and learnt that 
these features display different degrees of interdependence. 
We investigated the prognostic and predictive impact of the afore mentioned cell types in the 
tumour microenvironment and detected significant association of specific stroma, 
perivascular and macrophage markers with overall survival and of different stroma and 
macrophage markers on response to platinum-based therapy. 
Moreover, we described a range of phenotypes related to vascular, perivascular and stroma 
fibroblasts compositions of tumours, which might reflect the wide spectrum of sensitivity to 
anti-angiogenic therapy of different tumour types. Among these phenotypes, we identified 
serous ovarian cancer as belonging to a “tumour/vessel” and “perivascular- dependent” 
phenotype, compatible with an intermediate level of sensitivity to vessel-targeted drugs.  
We summarize our findings in a generic picture describing an “aggressive” type of serous 
ovarian cancer on one side, characterized by a bad prognosis, and a “resistant” type of serous 
ovarian cancer, characterized by the lowest sensitivity to therapy (figure 12). 
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Figure 12: Schematic representation of the “aggressive” HGSOC with poor prognosis and the “resistant 
HGSOC” with low sensitivity to platinum-based therapy.  The aggressive phenotype has high PDGFRß 
positive stroma fraction, high intensity of PDGFRß positive perivascular intensity, high heterogeneity of 
PDGFRß positive perivascular intensity and low density of CD11c positive macrophages. The resistant 
phenotype has high FAP+ stroma intensity, high CD8+ lymphocytes density, low CD80+ macrophages density. 
 
In the future, we aim at investigating the prognostic impact of the parameters analysed in 
paper I, II and III for serous ovarian cancer, in the more recent and better characterized cohort 
of high-grade serous ovarian cancer patients collected for study IV and V. We also aim to 
validate our candidate predictive markers from paper IV and V in an independent cohort of 
high-grade serous ovarian cancer patients and to explore them with regard to mechanism 
through experimental studies. 
Finally we would like to explore with different techniques such as immunofluorescence, 
confocal imaging and single-cell sequencing, the heterogeneity of stroma-derived cells in 
high-grade serous ovarian cancer.  
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Our data support future studies on the prognostic and predictive relevance of the different 
cells in the tumor microenvironment of ovarian cancer.   
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